Heart Failure POC & LOC Devices Market Research Report - Global Forecast till 2027

Heart Failure POC & LOC Devices Market Research Report: Information by Test type (Proteomic Testing, Metabolomic Testing, Genomic Testing), by Technology (Microfluidics, Array-based Systems), by End User (Hospitals & Clinics, Homecare, Specialty Centers, and Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027

ID: MRFR/HC/9169-HCR | August 2021 | Region: Global | 120 pages

Heart Failure POC and LOC Devices Market Forecast


The heart failure POC & LOC devices market is expected to cross ~USD 175.35 million by 2027 at a CAGR of~16.2%.


Market Overview:


Point-of-Care (POC) devices are used to get diagnostic results near the patients, where as Lab-On-Chip (LOC) devices integrate many laboratory operations on a single circuit to provide automation and high through put screening. POC assays are available to diagnose heart failure, and LOC device technology can be used for POC and central lab testing. For tackling the difficulties of health disparities, point-of-care testing detects cardiac indicators and other time-critical indicators. The factors such as an increase in cardiovascular diseases (CVDs),rise in the geriatric population, and increasing R&D for POC &LOC devicesare driving the global heart failure POC & LOC devices market. However, unfavorable reimbursement policies might hamper the market growth in the forecast period.


COVID-19 Analysis


The current pandemic of COVID-19 has affected people across the globe and resulted in the shutdown of operational facilities worldwide. The global economy has also suffered significantly, with the global GDP contracting by an estimated 5.2%, according to the World Bank in June 2020. During the lockdown, the healthcare business faced unforeseen challenges. As the manufacturing operations were shut down, production of medical devices and other healthcare products came to a halt. Furthermore, the medical supplies’ supply chain for was disrupted, leadingto an increase in stockpiling of manufactured goods.


This COVID-19 pandemic is also creating opportunities for the companies involved in the heart failure POC & LOC devices industry.According to a report by Northwestern University, US, in November 2020, many COVID-19 survivors will be at risk of chronic right heart failure, pulmonary hypertension, and diastolic dysfunction, especially those who have recovered from severe illness with significant hypoxemic respiratory failure and thromboembolic consequences.Furthermore, with the high demand for electronic health records, telehealth, and restrictions preventing patients from making in-person visits to diagnostic labs and hospitals,the demand for POC & LOC devices for heart failure is expected to increase.


Market Dynamics


Drivers


  • Increase in cardiovascular diseases


The increase in CVDs globally is expected to significantly drive the market for heart failure POC & LOC devices.LOC technology has the potential to improve disease diagnostics, whereas POC devices help measure specific cardiac biomarkers such as troponin.
According to WebMD, in December 2020, heart disease was the leading cause of death in the world, accounting foraround one-third of deaths in 2019, and the death toll is expected tocontinue rising. China accounted for the highest number of heart disease deaths in 2019, followed by India, Russia, the US, and Indonesia.Furthermore, as statedin a CDC report in 2018, about 655,000 Americans die from heart disease each year, i.e., 1 in every 4 deaths, the number onecause of death in the US. Thus, several major companies are racing to introduce high-quality devices and accessories for better management of data for patients with CVD. This rising patient pool has ultimately increased the demand for POC & LOC devices which would fuel the growth of the market.

Rise in geriatric population



  • Increasing R&D for POC & LOC devices


Market Opportunities


  • Increased funding for heart and cardiovascular disease research


As the global burden for CVD increases, there is a need for extensive R&D to find more efficient treatments and diagnostic methods to prevent the rapid rise of CVD disorders. The increase in R&D investments for heart and CVD will drive the heart failure POC & LOC devices market in the future as point-of-care testing (POCT) is a vital technology to diagnose CVDs such as heart failure.
According to a report published by New South Wales Government in June 2018, an investment of USD 190 million will be made over the decade for heart disease-related research. Furthermore, NIH funding for cardiovascular conditions has increased from USD 1,964 million in 2013 to an estimated USD 2,496 million in 2020. Therefore, such an increase in funding will supplement the heart failure POC & LOC devices market in the future.


  • Development of newer POC & LOC compatible heart failure biomarkers


Market Restraints


  • Ambiguous reimbursement policies


In most countries, delayed reimbursement, or lack of funding for diagnostics acts as a key barrier tomarket growth. Reimbursement for diagnostic tests is a complex process. The complexity in the reimbursement process itself acts as a challenge for this market. In most cases, reimbursement is granted for the process or technology, not for the value.

The problems in invoicing POC & LOC devices, effectively recording information, and a lack of acquaintance with regulatory rules are the reasons for the emergence of reimbursement concerns.Multiple techniques and Current Procedural Terminology (CPT) codes used for the same name are the main causes of billing issues forPOCT. This primarily applies to POCT devices that produce several findings simultaneously (many tests with one cartridge), where one test may be reimbursed but another may not. Hence, the ambiguity and complexity of reimbursement filing pose a barrier to heart failure POC & LOC devices market growth.


Regulatory Implications



  • The Clinical Laboratory Improvement Amendments (CLIA) of 1988 regulate all clinical testing in the US, regardless of where it is performed. POCT refers to non-laboratory employees doing CLIA waived or non-waived laboratory tests at remote locations. While there is little federal regulation of POCT, states and accrediting bodies frequently impose additional restrictions. POC testing regulatory requirements normally focus on two areas:



  1. Personnel training and competency

  2. Verification of strict adherence to the manufacturer-specified protocol for each test



  • The regulatory challenges for POC & LOC devices are the quality issues that arise as a result of users who are not trained or who lack the necessary competencies. Furthermore, factors such as the inadequate frequency of quality control, the complex documentation process, the cleaning and disinfection processes that should be followed, and maintaining consistency among central laboratory processes with POCT processes, as well as differences between different POCT device models, lead to more regulatory implications.


Segment Overview

By Test Type



  • Proteomic Testing


Circulating protein biomarkers can provide crucial information to clinicians about pathways in heart failure (HF). Researchers may now assess a largenumber of proteins simultaneously with high sensitivity and selectivity to detect low-abundance proteins due to advances in proteomics.Some protein markers that POC devices detect for heart failure areC-reactive protein (CRP),troponin, andB-type natriuretic peptide (BNP). Proteomic testing held the largest share in this segment due to factors like increased demand for accurate and efficient protein biomarkers such as troponin for the diagnosis and prevention of heart failure. 


  • Metabolomic Testing


Metabolomics refers to the study of small organic molecules found within different biochemical pathways.Patients with systolic heart failure have metabolomic profiles produced through serum and breath analysis, which can be used clinically for diagnosis and prognosis of heart failure. One example of metabolomic testing with POC & LOC devices for diagnosis of heart failure is blood lipid profile testing. 


  • Genomic Testing


Genomic testing enables diagnosis of heart failure by identifying whether the patient possesses an altered gene or genetic fault that may lead toInherited Heart Condition (IHC). In resource-constrained situations, laboratory-based detection technologies such as Polymerase Chain Reaction (PCR) are often unavailable due to a lack of advanced infrastructures, reliable electricity, and experienced operators. On the other hand, POCT allows for on-the-spot detections in these settings.

By Technology



  • Microfluidics


Microfluidics has inherent characteristics that make it particularly well suited to modeling the cardiovascular system.By incorporating microfluidics into POC testing, fluid manipulation and detection may be done in one device with minimum sample requirements. Microfluidics held the largest share in thetechnology segment in 2020 due to several advantages such as low reagent requirement, minimum sample, and high throughput. Moreover, microfluidics-based POC & LOC devices help in the detection and measurement of heart failure-related biomarkers, essential for heart failure diagnosis.


  • Array-based Systems


Array-based POC & LOC devices for heart failure work on two major principles of sandwich and competitive modes. Saliva analysis for the detection of heart failure symptoms is one application ofarray-basedPOC & LOC devices. The electronic taste chip (ETC) method is used in such LOC devices. On the ETC LOC system, C-reactive protein (CRP)is measured using a sandwich-type immunoassay.

By End User



  • Hospitals & Clinics


Point-of-care testing has tremendous applications in hospitals & clinics. Compared to central laboratory testing, POCT has a faster turnaround time for results and allows patients to return home sooner. This helps clinicians make quick medical decisions. All these factors make POC &LOC devices much advantageous for clinics to efficiently provide outpatient care and treat a larger patient pool in a short period.


  • Homecare


The use ofPOC & LOC devices for home use is also increasing as caretakers and patients prefer minimally invasive methods for health monitoring purposes. Furthermore, the ease of testing at home rather than visiting healthcare centers supplements the growth of this segment.


  • Specialty Centers


Specialty centers provide a complete range of heart failure diagnoses and treatment, including the use of heart failure POC & LOC devices. They contain specialists ranging from sleep disorders specialists to palliative care specialists to cover the complete process of diagnosis, treatment, and care of heart failure patients.


  • Others


Other end users include research laboratories and assisted living healthcare facilities where heart failure POC & LOC devices are employed.

Regional Analysis


North America



  • Increasing prevalence of heart disorders is driving the growth of the North American heart failure POC & LOC devicesmarket


North Americaholds the largest share in the heart failure POC & LOC devices market. This share is attributed to the high prevalence of heart diseases in the region. According to the Centers for Disease Control and Prevention (CDC), from 2015 to 2020, heart disease was the number one cause of death in the US. Furthermore, deaths from heart diseases increased by 4.8% in 2020, the highest number of deaths related to heart disease since 2012.  Hence, there is an increased demand for heart failure POC & LOC devices in the region. In addition, the presence of key players supplements the market growth in the region. 
Europe


  • Government initiatives and rising heart failure cases arefueling the Europeanheart failure POC & LOC devicesmarket


The Europeanheart failure POC & LOC devices market accounted to hold a significant market share in 2021. According to a report by United Arab Emirates University (UAE) in July 2020, Eastern European countries showed the highest prevalence of ischemic heart disease in the world in 2017, with a prevalence rate of 3,547 per 100,000 individuals. Furthermore, increase in government initiative such as fully funding the Kardiatool Project which ran from 2017 to 2021 aimed at monitoring heart failure patients with the help of an integrated POC solution is driving the market. In 2020, the European Commission funded the project with another USD 5.8 million. Therefore, the increasing prevalence of heart failure disorders and supporting government initiatives will drive the market in the forecast period.

Asia-Pacific



  • Increasing geriatric population and emerging economies are driving the growth of the heart failure POC & LOC devices market in the region


An increase in age has a direct correlation with heart failure cases, as higher age makes a person more susceptible to cardiovascular disorders. Countries within this region possess a high percentage of old age population, driving the growth of the market in the region. For instance, according to Population Reference Bureau in 2019, China had the highest population of old aged people (65 years and older),166.37 million older people in 2019.

Rest of the World



  • Improving healthcare facilities and supportive government regulations drive growth for the market in this region


The improving healthcare infrastructure in the region and government initiatives are driving the growth of the market. For instance, in February 2019, Phillips (Netherlands) collaborated with the Saudi Arabia Ministry of Health (MOH) to implement a Cardiovascular Information System (CVIS) integrated across the country, which will make heart failure diagnosis and treatment more efficient.

Competitive Landscape



  • Several global and local industry players are contributing to the market growth. One of the key players is Abbott (US). The companydiscovers, develops, manufactures, and sells healthcare products across the globe. It operates through four reportable segments, namely, established pharmaceutical products, diagnostic products, nutritional products, and vascular products. The medical devices segment offers devices for various treatments, including cardiac arrhythmias & heart failure, vascular, neuromodulation, structural heart, and diabetes care. Cholestech LDX analyzer and i-STAT Handheld product are two of its offerings for heart failure point-of-care testing. Abbott sells its products to customers in more than 160 countries.


List of companies with HQ


  • Abbott (US)

  • Hoffmann-La Roche Ltd. (Switzerland)

  • Danaher (US)

  • Abaxis, Inc. (US)

  • Quidel Corporation (US)

  • Siemens Healthineers (Germany)

  • Jant Pharmacal Corporation (US)

  • Trinity Biotech (Ireland)

  • bioMérieux S.A (France)

  • Instrumentation Laboratory Company (US)

  • Others


Recent Developments


  • In April 2021, Siemens Healthineers received the CE mark approval for the AtellicaVTLi Patient-Side Immunoassay Analyzer, a device that provides a point-of-care test to aid in the diagnosis of heart attacks.

  • In May2020, the FDA approved the use of Philips ultrasound portfolio to manage COVID-19-related pulmonary and heart problems. This will allow the performing ofcardiac ultrasound exams in different settings like an emergency department, an intensive care unit,or a specially designated ward for COVID-19 patients, which will reduce the risk of transmission of the virus.

  • In October 2020, Butterfly Network Inc. launched Butterfly iQ+ point-of-care-ultrasound (POCUS), which can help diagnose heart failure at the point-of-careand transform a mobile phone into an imaging system.


Report Overview


  • The study covers the existing short-term and long-term market effects. It helps decision-makers to draught short-term and long-term business plans by region. The report covers major regions in North America, Europe, Asia-Pacific, and the Rest of the World. The report analyzes market drivers, restraints, opportunities, challenges, Porter's five forces, value chain, and impact of COVID-19 on the market.


Market Segmentation:

Global Heart Failure POC & LOC Devices Market,By Test Type



  • Proteomic Testing

  • Metabolomic Testing

  • Genomic Testing


Global Heart Failure POC & LOC Devices Market, By Technology


  • Microfluidics

  • Array-based Systems

  • Others


Global Heart Failure POC & LOC Devices Market, By End User


  • Hospitals &Clinics

  • Homecare

  • Specialty Centers

  • Others


Global Heart Failure POC & LOC Devices Market, by Region


  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America





Report Scope:
Report Attribute/Metric Details
  Market Size   2027:~USD 61.77 Million
  CAGR   ~16.20%
  Base Year   2020
  Forecast Period   2021-2027
  Historical Data   2018 & 2019
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Test Type, Technology, and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World
  Key Vendors   Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher (US), Abaxis, Inc. (US), Quidel Corporation (US), Siemens Healthineers (Germany), JantPharmacal Corporation (US), Trinity Biotech (Ireland), bioMérieux S.A (France),Instrumentation Laboratory Company (US)
  Key Market Opportunities   • Increased funding for heart and cardiovascular disease research • Untapped Asia-Pacific region
  Key Market Drivers   • Increase in cardiovascular diseases • Rise in geriatric population • Increasing research and development for POC & LOC devices


TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Technology

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Impact on Supply Chain

5.3.3. Regional Impact

5.3.4. Opportunity and Threat Analysis

6. GLOBAL HEART FAILURE POC & LOC DEVICESMARKET, BY TEST TYPE

6.1. Overview

6.2. Proteomic Testing

6.3. Metabolomic Testing

6.4. Genomic Testing

7. GLOBAL HEART FAILURE POC & LOC DEVICESMARKET, BY TECHNOLOGY

7.1. Overview

7.2. Microfluidics

7.3. Array-based Systems

7.4. Others

8. GLOBAL HEART FAILURE POC & LOC DEVICESMARKET, BY END USER

8.1. Overview

8.2. Hospitals & Clinics

8.3. Homecare

8.4. Specialty Centers

8.5. Others

9. GLOBAL HEART FAILURE POC & LOC DEVICESMARKET, BY REGION

9.1. Overview

9.1. North America

9.1.1. US

9.1.2. Canada

9.2. Europe

9.2.1. Germany

9.2.2. France

9.2.3. UK

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. South Korea

9.3.5. Australia

9.3.6. Rest of Asia-Pacific

9.4. Rest of the World

9.4.1. Middle East

9.4.2. Africa

9.4.3. Latin America

10. COMPANY LANDSCAPE

10.1. Overview

10.2. Competitive Analysis

10.3. Market Share Analysis

10.4. Major Growth Strategy in the Global Heart Failure POC & LOC DevicesMarket

10.5. Competitive Benchmarking

10.6. Leading Players in terms of Number of Developments in the Global Heart Failure POC & LOC DevicesMarket

10.7. Key Developments and Growth Strategies

10.7.1. New ProductLaunch/Service Deployment

10.7.2. Merger &Acquisitions

10.7.3. Joint Ventures

10.8. Major Players Financial Matrix

10.8.1. Sales & Operating Income, 2020

10.8.2. Major Players R&D Expenditure, 2020

11. COMPANY PROFILES

11.1. Abbott (US)

11.1.1. Company Overview

11.1.2. Financial Overview

11.1.3. Products Offered

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. F. Hoffmann-La Roche Ltd. (Switzerland)

11.3. Danaher (US)

11.4. Abaxis, Inc. (US)

11.5. Quidel Corporation (US)

11.6. Siemens Healthineers (Germany)

11.7. Jant Pharmacal Corporation (US)

11.8. Trinity Biotech (Ireland)

11.9. bioMérieux S.A (France)

11.10. Instrumentation Laboratory Company (US)

11.11. Others

12. APPENDIX

12.1. References

12.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SYNOPSIS, 2018–2027

TABLE 2 GLOBAL HEART FAILURE POC & LOC DEVICES MARKET ESTIMATES & FORECAST, 2018–2027 (USD MILLION)

TABLE 3 GLOBAL HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 4 GLOBAL HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 5 GLOBAL HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 6 NORTH AMERICA: HEART FAILURE POC & LOC DEVICES MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 7 NORTH AMERICA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 8 NORTH AMERICA HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 9 NORTH AMERICA: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 10 US: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 11 US HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 12 US: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 13 CANADA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 14 CANADA HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 15 CANADA: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 16 EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 17 EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 18 EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 19 EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 20 GERMANY: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 21 GERMANY: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 22 GERMANY: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 23 FRANCE: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 24 FRANCE: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 25 FRANCE: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 26 ITALY: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 27 ITALY: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 28 ITALY: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 29 SPAIN: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 30 SPAIN: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 31 SPAIN: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 32 UK: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 33 UK: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 34 UK: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 35 REST OF EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 36 REST OF EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 37 REST OF EUROPE: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 40 ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 41 ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 42 JAPAN: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 43 JAPAN: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 44 JAPAN: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 45 CHINA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 46 CHINA: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 47 CHINA: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 48 INDIA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 49 INDIA: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 50 INDIA: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 51 AUSTRALIA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 52 AUSTRALIA: HEART FAILURE POC & LOC DEVICES MARKET, TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 53 AUSTRALIA: HEART FAILURE POC & LOC DEVICES MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 54 SOUTH KOREA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 55 SOUTH KOREA: HEART FAILURE POC & LOC DEVICES MARKET, TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 56 SOUTH KOREA: HEART FAILURE POC & LOC DEVICES MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 57 REST OF ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 58 REST OF ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY TECHNOLOGY, 2018–2027 (USD MILLION)

TABLE 59 REST OF ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICES MARKET, BY END USER, 2018–2027 (USD MILLION)

TABLE 60 REST OF THE WORLD: HEART FAILURE POC & LOC DEVICES MARKET, BY COUNTRY, 2018–2027 (USD MILLION)

TABLE 61 REST OF THE WORLD: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 62 REST OF THE WORLD: HEART FAILURE POC & LOC DEVICES MARKET, TECHNOLOGY 2018–2027 (USD MILLION)

TABLE 63 REST OF THE WORLD: HEART FAILURE POC & LOC DEVICES MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 64 MIDDLE EAST: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 65 MIDDLE EAST: HEART FAILURE POC & LOC DEVICES MARKET, TECHNOLOGY 2018–2027 (USD MILLION)

TABLE 66 MIDDLE EAST: HEART FAILURE POC & LOC DEVICES MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 67 AFRICA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 68 AFRICA: HEART FAILURE POC & LOC DEVICES MARKET, TECHNOLOGY 2018–2027 (USD MILLION)

TABLE 69 AFRICA: HEART FAILURE POC & LOC DEVICES MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 70 LATIN AMERICA: HEART FAILURE POC & LOC DEVICES MARKET, BY TEST TYPE, 2018–2027 (USD MILLION)

TABLE 71 LATIN AMERICA: HEART FAILURE POC & LOC DEVICES MARKET, TECHNOLOGY 2018–2027 (USD MILLION)

TABLE 72 LATIN AMERICA: HEART FAILURE POC & LOC DEVICES MARKET, END USER, 2018–2027 (USD MILLION)

TABLE 73 MAJOR MANUFACTURERS IN THE GLOBAL HEART FAILURE POC & LOC DEVICES MARKET

TABLE 74 MOST ACTIVE PLAYER IN THE GLOBAL HEART FAILURE POC & LOC DEVICES MARKET

TABLE 75 PRODUCT LAUNCH/PRODUCT APPROVAL

TABLE 76 PARTNERSHIP/AGREEMENT

TABLE 77 ACQUISITIONS

TABLE 78 EXPANSION

TABLE 79 ABBOTT: PRODUCTS/SERVICES OFFERED

TABLE 80 ABBOTT: KEY DEVELOPMENTS

TABLE 81 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED

TABLE 82 F. HOFFMANN-LA ROCHE LTD.: KEY DEVELOPMENTS

TABLE 83 DANAHER: PRODUCTS/SERVICES OFFERED

TABLE 84 DANAHER: KEY DEVELOPMENTS

TABLE 85 ABAXIS, INC.: PRODUCTS/SERVICES OFFERED

TABLE 86 ABAXIS, INC.: KEY DEVELOPMENTS

TABLE 87 QUIDEL CORPORATION: PRODUCTS/SERVICES OFFERED

TABLE 88 QUIDEL CORPORATION: KEY DEVELOPMENTS

TABLE 89 SIEMENS HEALTHINEERS: PRODUCTS/SERVICES OFFERED

TABLE 90 SIEMENS HEALTHINEERS: KEY DEVELOPMENTS

TABLE 91 JANT PHARMACAL CORPORATION: PRODUCTS/SERVICES OFFERED

TABLE 92 JANT PHARMACAL CORPORATION: KEY DEVELOPMENTS

TABLE 93 TRINITY BIOTECH: PRODUCTS/SERVICES OFFERED

TABLE 94 TRINITY BIOTECH: KEY DEVELOPMENTS

TABLE 95 BIOMÉRIEUX S.A.: PRODUCTS/SERVICES OFFERED

TABLE 96 BIOMÉRIEUX S.A.: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL HEART FAILURE POC & LOC DEVICESMARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL HEART FAILURE POC & LOC DEVICESMARKET

FIGURE 4 GLOBAL HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY TEST TYPE, 2020 (%)

FIGURE 5 GLOBAL HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY TECHNOLOGY, 2020 (%)

FIGURE 6 GLOBAL HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY REGION, 2020 (%)

FIGURE 9 EUROPE: HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 ASIA-PACIFIC: HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 REST OF THE WORLD: HEART FAILURE POC & LOC DEVICESMARKET SHARE, BY REGION, 2020 (%)

FIGURE 12 GLOBAL HEART FAILURE POC & LOC DEVICESMARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 13 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 14 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL HEART FAILURE POC & LOC DEVICES MARKET

FIGURE 15 GLOBAL HEART FAILURE POC & LOC DEVICES MARKET: COMPETITIVE LANDSCAPE

FIGURE 16 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 ABBOTT: SWOT ANALYSIS

FIGURE 18 F. HOFFMANN-LA ROCHE LTD.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 F. HOFFMANN-LA ROCHE LTD.:SWOT ANALYSIS

FIGURE 20 DANAHER:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 DANAHER.:SWOT ANALYSIS

FIGURE 22 ABAXIS, INC.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 ABAXIS, INC.:SWOT ANALYSIS

FIGURE 24 QUIDEL CORPORATION:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 QUIDEL CORPORATION:SWOT ANALYSIS

FIGURE 26 SIEMENS HEALTHINEERS:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 SIEMENS HEALTHINEERS:SWOT ANALYSIS

FIGURE 28 JANT PHARMACAL CORPORATION:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 JANT PHARMACAL CORPORATION:SWOT ANALYSIS

FIGURE 30 TRINITY BIOTECH: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 TRINITY BIOTECH: SWOT ANALYSIS

FIGURE 32 BIOMÉRIEUX S.A.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 BIOMÉRIEUX S.A.: SWOT ANALYSIS

FIGURE 34 INSTRUMENTATION LABORATORY COMPANY (US):FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 INSTRUMENTATION LABORATORY COMPANY (US):SWOT ANALYSIS



This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.